Michael D. Abramoff, MD, PhD, Founder and Executive Chairman of Digital Diagnostics, has co-authored a study showcasing the impact of LumineticsCore™. The study, which was published by Nature Digital Medicine and co-authored by experts from Johns Hopkins University and the University of Wisconsin-Madison, demonstrates that LumineticsCore significantly increases testing rates for diabetic retinopathy eye exams and enhances healthcare access and health equity, especially among underserved populations.
Autonomous artificial intelligence for diabetic eye disease increases access and health equity in underserved populations